Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 856 to 870 of 1688 results for carers

  1. Low-energy contact X-ray brachytherapy (the Papillon technique) for locally advanced rectal cancer

    Awaiting development [GID-IPG10412] Expected publication date: 13 November 2025

    Interventional procedures guidance
    Awaiting development

  2. Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)

    Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) caused by neurological conditions in adults.

    Technology appraisal guidance
    Published
    9 October 2019
    View recommendations

    Sections for TA605

  3. Pembrolizumab with lenvatinib for untreated PD-L1 positive recurrent or metastatic squamous cell head and neck cancer [ID5118]

    In development [GID-TA11005] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]

    In development [GID-TA11410] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6161]

    Awaiting development [GID-TA11099] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6162]

    Awaiting development [GID-TA11101] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Subcutaneous nivolumab for treating advanced renal cell carcinoma after systemic treatment TSID 12008

      Status ...

    Technology appraisal guidance
    Topic selection

  8. Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma [ID6202]

    In development [GID-TA11164] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124]

    Awaiting development [GID-TA11019] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]

    Awaiting development [GID-TA11343] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Tocilizumab for the treatment of systemic juvenile idiopathic arthritis (TA238)

    Evidence-based recommendations on tocilizumab (RoActemra), for treating systemic juvenile idiopathic arthritis in people aged 2 and over.

    Technology appraisal guidance
    Published
    14 December 2011
    View recommendations

    Sections for TA238

  12. Pancreatic cancer (QS177)

    This quality standard covers diagnosis of pancreatic cancer and management of pancreatic ductal adenocarcinoma in adults aged over 18. This quality standard describes high-quality care in priority areas for improvement. It does not cover national initiatives, such as cancer screening or audit.

    Quality standard
    Published
    20 December 2018
    View quality statements

    Sections for QS177

  13. Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA963) [ID6426]

    Awaiting development [GID-TA11536] Expected publication date: 21 May 2025

    Technology appraisal guidance
    Awaiting development

  14. Bed frames for adults in acute settings

    In development [GID-HTE10050] Expected publication date: 28 May 2025

    Health technology evaluations
    In development

  15. Epcoritamab for treating relapsed or refractory follicular lymphoma ID6338

    In development [GID-TA11385] Expected publication date: TBC

    Technology appraisal guidance
    In development